Titre : Traitements médicamenteux de la COVID-19

Traitements médicamenteux de la COVID-19 : Questions médicales fréquentes

Termes MeSH sélectionnés :

Combined Modality Therapy

Questions fréquentes et termes MeSH associés

Prévention 5

#1

Les vaccins préviennent-ils la COVID-19 ?

Oui, les vaccins réduisent le risque d'infection et de formes graves de la maladie.
Vaccins Prévention
#2

Quelles mesures de prévention sont recommandées ?

Le port du masque, la distanciation sociale et le lavage des mains sont essentiels.
Mesures de prévention COVID-19
#3

Les traitements préventifs existent-ils ?

Des traitements comme les anticorps monoclonaux peuvent être utilisés en prévention chez certains patients.
Anticorps monoclonaux Prévention
#4

Les masques chirurgicaux sont-ils efficaces ?

Oui, ils réduisent la transmission du virus en filtrant les gouttelettes respiratoires.
Masques Transmission virale
#5

La vaccination est-elle obligatoire ?

Cela dépend des réglementations locales, mais elle est fortement recommandée.
Vaccination COVID-19

Traitements 5

#1

Quels médicaments sont utilisés pour traiter la COVID-19 ?

Des antiviraux comme le remdesivir et des corticostéroïdes comme la dexaméthasone sont utilisés.
Remdesivir Dexaméthasone
#2

Comment fonctionne le remdesivir ?

Le remdesivir inhibe la réplication du virus en bloquant l'ARN polymérase virale.
Remdesivir Antiviraux
#3

La dexaméthasone est-elle efficace pour tous les patients ?

Elle est efficace principalement chez les patients gravement malades nécessitant de l'oxygène.
Dexaméthasone COVID-19
#4

Quels sont les effets secondaires des traitements ?

Les effets secondaires peuvent inclure des infections, des troubles gastro-intestinaux et des réactions allergiques.
Effets secondaires Traitements médicamenteux
#5

Les antibiotiques sont-ils utiles contre la COVID-19 ?

Non, les antibiotiques ne traitent pas les infections virales comme la COVID-19.
Antibiotiques COVID-19

Complications 5

#1

Quelles sont les complications possibles de la COVID-19 ?

Les complications incluent la pneumonie, le syndrome de détresse respiratoire et des problèmes cardiaques.
Complications COVID-19
#2

Comment la COVID-19 affecte-t-elle le cœur ?

Elle peut provoquer des myocardites et des arythmies, augmentant le risque de complications cardiaques.
Myocardite COVID-19
#3

Les séquelles de la COVID-19 sont-elles fréquentes ?

Oui, de nombreux patients présentent des symptômes persistants, appelés COVID long.
COVID long Séquelles
#4

La COVID-19 peut-elle affecter le système nerveux ?

Oui, des symptômes neurologiques comme des maux de tête et des troubles de l'odorat peuvent survenir.
Système nerveux COVID-19
#5

Quels sont les risques de thrombose ?

La COVID-19 augmente le risque de thrombose veineuse et d'embolie pulmonaire.
Thrombose COVID-19

Facteurs de risque 5

#1

Quels sont les principaux facteurs de risque ?

Les facteurs incluent l'âge avancé, les maladies chroniques et l'obésité.
Facteurs de risque COVID-19
#2

Les personnes immunodéprimées sont-elles plus à risque ?

Oui, elles présentent un risque accru de formes graves de la COVID-19.
Immunodépression COVID-19
#3

Le sexe influence-t-il la gravité de la maladie ?

Oui, des études montrent que les hommes peuvent avoir des formes plus graves que les femmes.
Sexe COVID-19
#4

Les antécédents médicaux jouent-ils un rôle ?

Oui, des antécédents de maladies respiratoires ou cardiovasculaires augmentent le risque.
Antécédents médicaux COVID-19
#5

L'origine ethnique influence-t-elle le risque ?

Certaines études suggèrent que certaines ethnies peuvent être plus touchées par la COVID-19.
Origine ethnique COVID-19
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Traitements médicamenteux de la COVID-19 : Questions médicales les plus fréquentes", "headline": "Traitements médicamenteux de la COVID-19 : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Traitements médicamenteux de la COVID-19 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-01-17", "dateModified": "2025-04-11", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Traitements médicamenteux de la COVID-19" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Traitement médicamenteux", "url": "https://questionsmedicales.fr/mesh/D004358", "about": { "@type": "MedicalCondition", "name": "Traitement médicamenteux", "code": { "@type": "MedicalCode", "code": "D004358", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "E02.319" } } }, "about": { "@type": "MedicalCondition", "name": "Traitements médicamenteux de la COVID-19", "alternateName": "COVID-19 Drug Treatment", "code": { "@type": "MedicalCode", "code": "D000093485", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Didier Raoult", "url": "https://questionsmedicales.fr/author/Didier%20Raoult", "affiliation": { "@type": "Organization", "name": "Aix-Marseille Université, IRD, APHM, MEPHI, Faculté de Médecine et de Pharmacie, 19-21 boulevard Jean Moulin, 13385 Marseille Cedex 05, France; IHU-Méditerranée Infection, 19-21 boulevard Jean Moulin, 13385 Marseille Cedex 05, France." } }, { "@type": "Person", "name": "Francesco Potì", "url": "https://questionsmedicales.fr/author/Francesco%20Pot%C3%AC", "affiliation": { "@type": "Organization", "name": "Department of Medicine and Surgery - Unit of Neurosciences, University of Parma, Parma, Italy. francesco.poti@unipr.it." } }, { "@type": "Person", "name": "Taher Entezari-Maleki", "url": "https://questionsmedicales.fr/author/Taher%20Entezari-Maleki", "affiliation": { "@type": "Organization", "name": "Department of Clinical Pharmacy, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran. tentezari@gmail.com." } }, { "@type": "Person", "name": "None None", "url": "https://questionsmedicales.fr/author/None%20None", "affiliation": { "@type": "Organization", "name": "" } }, { "@type": "Person", "name": "David Brandariz-Nuñez", "url": "https://questionsmedicales.fr/author/David%20Brandariz-Nu%C3%B1ez", "affiliation": { "@type": "Organization", "name": "Servicio de Farmacia, Hospital Quironsalud, Barcelona, España. Electronic address: vrandariz@gmail.com." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Survivorship in Early-Stage Rectal Cancer Patients Who Have Received Combined Modality Therapy.", "datePublished": "2023-08-06", "url": "https://questionsmedicales.fr/article/37586927", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.clcc.2023.08.002" } }, { "@type": "ScholarlyArticle", "name": "Combined modality therapy for patients with esophageal squamous cell carcinoma: Radiation dose and survival analyses.", "datePublished": "2022-11-09", "url": "https://questionsmedicales.fr/article/36351568", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/1759-7714.14724" } }, { "@type": "ScholarlyArticle", "name": "Cost-Effectiveness of PET Directed Versus Combined Modality Therapy for Early-Stage Favorable Hodgkin's Lymphoma.", "datePublished": "2022-07-17", "url": "https://questionsmedicales.fr/article/35963771", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.clml.2022.07.005" } }, { "@type": "ScholarlyArticle", "name": "Assessment of Patient-Reported Outcomes in Patients With Anal Squamous-Cell Cancer Undergoing Combined Modality Therapy.", "datePublished": "2022-09-05", "url": "https://questionsmedicales.fr/article/36102865", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1097/DCR.0000000000002600" } }, { "@type": "ScholarlyArticle", "name": "PET-directed combined modality therapy for gastroesophageal junction cancer: Results of the multicentre prospective MEMORI trial of the German Cancer Consortium (DKTK).", "datePublished": "2022-09-10", "url": "https://questionsmedicales.fr/article/36099671", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.ejca.2022.07.027" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Thérapeutique", "item": "https://questionsmedicales.fr/mesh/D013812" }, { "@type": "ListItem", "position": 3, "name": "Traitement médicamenteux", "item": "https://questionsmedicales.fr/mesh/D004358" }, { "@type": "ListItem", "position": 4, "name": "Traitements médicamenteux de la COVID-19", "item": "https://questionsmedicales.fr/mesh/D000093485" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Traitements médicamenteux de la COVID-19 - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Traitements médicamenteux de la COVID-19", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-12", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Traitements médicamenteux de la COVID-19", "description": "Les vaccins préviennent-ils la COVID-19 ?\nQuelles mesures de prévention sont recommandées ?\nLes traitements préventifs existent-ils ?\nLes masques chirurgicaux sont-ils efficaces ?\nLa vaccination est-elle obligatoire ?", "url": "https://questionsmedicales.fr/mesh/D000093485?mesh_terms=Combined+Modality+Therapy#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Traitements médicamenteux de la COVID-19", "description": "Quels médicaments sont utilisés pour traiter la COVID-19 ?\nComment fonctionne le remdesivir ?\nLa dexaméthasone est-elle efficace pour tous les patients ?\nQuels sont les effets secondaires des traitements ?\nLes antibiotiques sont-ils utiles contre la COVID-19 ?", "url": "https://questionsmedicales.fr/mesh/D000093485?mesh_terms=Combined+Modality+Therapy#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Traitements médicamenteux de la COVID-19", "description": "Quelles sont les complications possibles de la COVID-19 ?\nComment la COVID-19 affecte-t-elle le cœur ?\nLes séquelles de la COVID-19 sont-elles fréquentes ?\nLa COVID-19 peut-elle affecter le système nerveux ?\nQuels sont les risques de thrombose ?", "url": "https://questionsmedicales.fr/mesh/D000093485?mesh_terms=Combined+Modality+Therapy#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Traitements médicamenteux de la COVID-19", "description": "Quels sont les principaux facteurs de risque ?\nLes personnes immunodéprimées sont-elles plus à risque ?\nLe sexe influence-t-il la gravité de la maladie ?\nLes antécédents médicaux jouent-ils un rôle ?\nL'origine ethnique influence-t-elle le risque ?", "url": "https://questionsmedicales.fr/mesh/D000093485?mesh_terms=Combined+Modality+Therapy#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Les vaccins préviennent-ils la COVID-19 ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les vaccins réduisent le risque d'infection et de formes graves de la maladie." } }, { "@type": "Question", "name": "Quelles mesures de prévention sont recommandées ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Le port du masque, la distanciation sociale et le lavage des mains sont essentiels." } }, { "@type": "Question", "name": "Les traitements préventifs existent-ils ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Des traitements comme les anticorps monoclonaux peuvent être utilisés en prévention chez certains patients." } }, { "@type": "Question", "name": "Les masques chirurgicaux sont-ils efficaces ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils réduisent la transmission du virus en filtrant les gouttelettes respiratoires." } }, { "@type": "Question", "name": "La vaccination est-elle obligatoire ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Cela dépend des réglementations locales, mais elle est fortement recommandée." } }, { "@type": "Question", "name": "Quels médicaments sont utilisés pour traiter la COVID-19 ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Des antiviraux comme le remdesivir et des corticostéroïdes comme la dexaméthasone sont utilisés." } }, { "@type": "Question", "name": "Comment fonctionne le remdesivir ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Le remdesivir inhibe la réplication du virus en bloquant l'ARN polymérase virale." } }, { "@type": "Question", "name": "La dexaméthasone est-elle efficace pour tous les patients ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Elle est efficace principalement chez les patients gravement malades nécessitant de l'oxygène." } }, { "@type": "Question", "name": "Quels sont les effets secondaires des traitements ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Les effets secondaires peuvent inclure des infections, des troubles gastro-intestinaux et des réactions allergiques." } }, { "@type": "Question", "name": "Les antibiotiques sont-ils utiles contre la COVID-19 ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Non, les antibiotiques ne traitent pas les infections virales comme la COVID-19." } }, { "@type": "Question", "name": "Quelles sont les complications possibles de la COVID-19 ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent la pneumonie, le syndrome de détresse respiratoire et des problèmes cardiaques." } }, { "@type": "Question", "name": "Comment la COVID-19 affecte-t-elle le cœur ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Elle peut provoquer des myocardites et des arythmies, augmentant le risque de complications cardiaques." } }, { "@type": "Question", "name": "Les séquelles de la COVID-19 sont-elles fréquentes ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, de nombreux patients présentent des symptômes persistants, appelés COVID long." } }, { "@type": "Question", "name": "La COVID-19 peut-elle affecter le système nerveux ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des symptômes neurologiques comme des maux de tête et des troubles de l'odorat peuvent survenir." } }, { "@type": "Question", "name": "Quels sont les risques de thrombose ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "La COVID-19 augmente le risque de thrombose veineuse et d'embolie pulmonaire." } }, { "@type": "Question", "name": "Quels sont les principaux facteurs de risque ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent l'âge avancé, les maladies chroniques et l'obésité." } }, { "@type": "Question", "name": "Les personnes immunodéprimées sont-elles plus à risque ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles présentent un risque accru de formes graves de la COVID-19." } }, { "@type": "Question", "name": "Le sexe influence-t-il la gravité de la maladie ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des études montrent que les hommes peuvent avoir des formes plus graves que les femmes." } }, { "@type": "Question", "name": "Les antécédents médicaux jouent-ils un rôle ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents de maladies respiratoires ou cardiovasculaires augmentent le risque." } }, { "@type": "Question", "name": "L'origine ethnique influence-t-elle le risque ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Certaines études suggèrent que certaines ethnies peuvent être plus touchées par la COVID-19." } } ] } ] }
Dr Olivier Menir

Contenu validé par Dr Olivier Menir

Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale


Validation scientifique effectuée le 11/04/2025

Contenu vérifié selon les dernières recommandations médicales

Auteurs principaux

Didier Raoult

2 publications dans cette catégorie

Affiliations :
  • Aix-Marseille Université, IRD, APHM, MEPHI, Faculté de Médecine et de Pharmacie, 19-21 boulevard Jean Moulin, 13385 Marseille Cedex 05, France; IHU-Méditerranée Infection, 19-21 boulevard Jean Moulin, 13385 Marseille Cedex 05, France.
Publications dans "Traitements médicamenteux de la COVID-19" :

Francesco Potì

2 publications dans cette catégorie

Affiliations :
  • Department of Medicine and Surgery - Unit of Neurosciences, University of Parma, Parma, Italy. francesco.poti@unipr.it.
Publications dans "Traitements médicamenteux de la COVID-19" :

Taher Entezari-Maleki

2 publications dans cette catégorie

Affiliations :
  • Department of Clinical Pharmacy, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran. tentezari@gmail.com.
  • Cardiovascular Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. tentezari@gmail.com.
Publications dans "Traitements médicamenteux de la COVID-19" :

None None

2 publications dans cette catégorie

Publications dans "Traitements médicamenteux de la COVID-19" :

David Brandariz-Nuñez

2 publications dans cette catégorie

Affiliations :
  • Servicio de Farmacia, Hospital Quironsalud, Barcelona, España. Electronic address: vrandariz@gmail.com.
Publications dans "Traitements médicamenteux de la COVID-19" :

Marcelo Correas-Sanahuja

2 publications dans cette catégorie

Affiliations :
  • Servicio de Farmacia, Hospital CIMA, Barcelona, España.
Publications dans "Traitements médicamenteux de la COVID-19" :

Eva Guarc

2 publications dans cette catégorie

Affiliations :
  • Servicio de Farmacia, Hospital Quironsalud, Barcelona, España.
Publications dans "Traitements médicamenteux de la COVID-19" :

Rafael Picón

2 publications dans cette catégorie

Affiliations :
  • Servicio de Farmacia, Hospital Quironsalud, Barcelona, España.
Publications dans "Traitements médicamenteux de la COVID-19" :

Bárbara García

2 publications dans cette catégorie

Affiliations :
  • Servicio de Farmacia, Hospital Quironsalud, Barcelona, España.
Publications dans "Traitements médicamenteux de la COVID-19" :

Rocío Gil

2 publications dans cette catégorie

Affiliations :
  • Servicio de Farmacia, Hospital Quironsalud, Barcelona, España.
Publications dans "Traitements médicamenteux de la COVID-19" :

Vincent K C Yan

2 publications dans cette catégorie

Affiliations :
  • Centre for Safe Medication Practice and Research Department of Pharmacology and Pharmacy LKS Faculty of Medicine University of Hong Kong Hong Kong Special Administrative Region, 1/F, Jockey Club Building for Interdisciplinary Research, 5 Sassoon Road Pokfulam Hong Kong SAR China.
Publications dans "Traitements médicamenteux de la COVID-19" :

Xiaodong Li

2 publications dans cette catégorie

Affiliations :
  • Department of Computer Science Faculty of Engineering University of Hong Kong Hong Kong Special Administrative Region, CB303, Chow Yei Ching Building Pokfula Hong Kong SAR China.
Publications dans "Traitements médicamenteux de la COVID-19" :

Xuxiao Ye

2 publications dans cette catégorie

Affiliations :
  • Centre for Safe Medication Practice and Research Department of Pharmacology and Pharmacy LKS Faculty of Medicine University of Hong Kong Hong Kong Special Administrative Region, 1/F, Jockey Club Building for Interdisciplinary Research, 5 Sassoon Road Pokfulam Hong Kong SAR China.
Publications dans "Traitements médicamenteux de la COVID-19" :

Min Ou

2 publications dans cette catégorie

Affiliations :
  • Department of Computer Science Faculty of Engineering University of Hong Kong Hong Kong Special Administrative Region, CB303, Chow Yei Ching Building Pokfula Hong Kong SAR China.
Publications dans "Traitements médicamenteux de la COVID-19" :

Ruibang Luo

2 publications dans cette catégorie

Affiliations :
  • Department of Computer Science Faculty of Engineering University of Hong Kong Hong Kong Special Administrative Region, CB303, Chow Yei Ching Building Pokfula Hong Kong SAR China.
Publications dans "Traitements médicamenteux de la COVID-19" :

Qingpeng Zhang

2 publications dans cette catégorie

Affiliations :
  • School of Data Science City University of Hong Kong Hong Kong Special Administrative Region, 83 Tat Chee Avenue Kowloon Hong Kong SAR China.
Publications dans "Traitements médicamenteux de la COVID-19" :

Bo Tang

2 publications dans cette catégorie

Affiliations :
  • Department of Computer Science and Engineering Southern University of Science and Technology 1088 Xueyuan Avenue, Nanshan District Shenzhen Guangdong 518055 China.
Publications dans "Traitements médicamenteux de la COVID-19" :

Benjamin J Cowling

2 publications dans cette catégorie

Affiliations :
  • Division of Epidemiology and Biostatistics School of Public Health University of Hong Kong Hong Kong Special Administrative Region, 21 Sassoon Road Pokfulam Hong Kong SAR China.
Publications dans "Traitements médicamenteux de la COVID-19" :

Ivan Hung

2 publications dans cette catégorie

Affiliations :
  • Division of Infectious Diseases Department of Medicine LKS Faculty of Medicine University of Hong Kong Hong Kong Special Administrative Region, 102 Pokfulam Road Hong Kong SAR China.
Publications dans "Traitements médicamenteux de la COVID-19" :

Chung Wah Siu

2 publications dans cette catégorie

Affiliations :
  • Division of Cardiology Department of Medicine University of Hong Kong Hong Kong Special Administrative Region, 102 Pokfulam Road Hong Kong SAR China.
Publications dans "Traitements médicamenteux de la COVID-19" :

Sources (10000 au total)

Combined modality therapy for patients with esophageal squamous cell carcinoma: Radiation dose and survival analyses.

We aimed to analyze the radiation dose and compare survival among combined modality therapy using modern radiation techniques for patients with esophageal squamous cell carcinoma (ESCC).... This retrospective study included patients with clinically staged T1-4N0-3M0 ESCC from 2014 to 2018. Patients who received combined modality therapies with curative intent were enrolled. The overall s... Of the 259 patients, 141 (54.4%) received definitive concurrent chemoradiotherapy (DCCRT); 67 (25.9%) underwent neoadjuvant chemoradiotherapy followed by surgery (NCRT+S); 51 (19.7%) obtained surgery ... Our results suggest that NCRT+S can provide a favorable survival for patients with ESCC, especially in patients who achieved pCR. The optimal radiation dose might be 55-60 Gy for patients receiving DC...

Cost-Effectiveness of PET Directed Versus Combined Modality Therapy for Early-Stage Favorable Hodgkin's Lymphoma.

The standard of care for early-stage Hodgkin Lymphoma (HL) is combined modality therapy (CMT) consisting of chemotherapy and involved site radiation therapy (ISRT). Recent treatment de-escalation tria... This study used a cost-effectiveness Markov model simulating 5 year outcomes for 1 million patients with early-stage HL treated with either PET-directed therapy consisting of 2 cycles of ABVD chemothe... We found that PET-directed therapy and CMT strategies were associated with costs of $47,362 and $41,167, respectively. The CMT strategy was equally as effective as the PET-directed therapy strategy wi... For patients with early-stage HL, CMT is the cost-effective strategy as compared with PET-directed therapy....

Assessment of Patient-Reported Outcomes in Patients With Anal Squamous-Cell Cancer Undergoing Combined Modality Therapy.

There is limited knowledge on long-term bowel, sexual, and urinary function after combined modality therapy for anal squamous-cell cancer.... This study aimed to evaluate long-term changes in patients treated with combined modality.... This was a retrospective study of prospectively collected patient-reported outcome surveys.... This study was conducted at a single institution.... There were 143 patients with stage I to III anal cancer who were treated with chemoradiation and had completed the survey.... This study included patient-reported outcomes reflecting bowel, sexual, and urinary function.... Thirty-nine percent of patients had major low anterior resection syndrome at baseline. Major low anterior resection syndrome remained stable (38%; 95% CI, 31%-46%) with no change over time (OR 0.95; 9... This was a single-institution study and only patients who answered the questionnaire were included in the study.... A significant proportion of patients have major low anterior resection syndrome at baseline and after successful treatment for anal cancer. Having major low anterior resection syndrome at baseline was... ANTECEDENTES:Existe un conocimiento limitado sobre la función intestinal, sexual y urinaria a largo plazo después de la terapia de modalidad combinada para el cáncer anal de células escamosas.OBJETIVO...

PET-directed combined modality therapy for gastroesophageal junction cancer: Results of the multicentre prospective MEMORI trial of the German Cancer Consortium (DKTK).

Positron emission tomography (PET) may differentiate responding and non-responding tumours early in the treatment of locally advanced gastroesophageal junction adenocarcinomas. Early PET non-responder... Patients underwent baseline... In total, 160 patients with resectable gastroesophageal junction adenocarcinomas were prospectively investigated by PET scanning. Eighty-five patients (53%) were excluded. Seventy-five eligible patien... The primary endpoint of the study to increase the R0 resection rate in metabolic NR was not met. PET response after induction CTX is prognostic for outcome with a prolonged OS and DFS in PET responder... NCT00002014-000860-16....

Neurotoxins and Combination Therapies.

Facial aging involves multilevel changes, extending from the skin to deep support structures. A comprehensive treatment approach targeting the many aspects of facial dynamics and architecture is often... To explore the integration of botulinum toxin type A (BoNT-A) into multimodal aesthetic treatment plans.... This article reviews evidence supporting the combination of BoNT-A with other minimally invasive cosmetic therapies, including dermal fillers, lasers, and energy-based devices as well as with plastic ... Combination treatment protocols including BoNT-A demonstrate higher patient satisfaction and retention rates compared to monotherapy or sequential treatments. Some guidelines for sequencing of treatme... Integrating BoNT-A into a larger aesthetic treatment plan is crucial for achieving natural and satisfying results in facial rejuvenation. Evidence supports better outcomes when incorporating with both...

Combination therapies for cancer: challenges and opportunities.

Gastrointestinal cancers represent a major challenge to public health. Pancreatic cancer is the most lethal cancer among all gastrointestinal cancers. Most patients cannot meet the criteria of resecti... Neoadjuvant chemotherapy helps some patients regain the opportunity of radical resection. An optimal regimen of chemotherapy is one that maximizes the anti-tumor efficacy while maintaining a relativel... Combination therapies in a multidisciplinary manner that involves modified chemotherapy regimen, radical resection, and intestine auto-transplantation may provide the currently best possible care to p...

Radiation Therapy With Combination Therapy of Immune Checkpoint Inhibitors and Antiangiogenic Therapy for Hepatocellular Carcinoma.

Immune checkpoint inhibitors (ICIs) combined with antiangiogenic therapy have limited efficacy in treating advanced hepatocellular carcinoma (HCC). The synergistic effect of systemic therapy and radia... This retrospective observational study analyzed the medical records of 194 patients with Barcelona Clinic Liver Cancer stage C HCC who were admitted to our center from August 2018 to June 2022 and rec... A total of 76 patients diagnosed with advanced-stage HCC and treated with ICIs and antiangiogenic therapy were included in the study, with 33 patients in the RT group and 43 patients in the non-RT gro... In comparison to the combination of ICIs and antiangiogenic therapy, the inclusion of RT has been observed to improve the DCR and survival outcomes in patients with advanced-stage HCC. The safety prof...